HLB Genex

Founded in 2000 as a fermentation- and protein-engineering-based industrial enzyme company, the firm listed on KOSDAQ in 2015 and changed its name after joining the HLB Group in 2024.

Its core business is specialty industrial enzymes such as Catalase, used in wastewater treatment for semiconductor and textile processes, and Lactase, used to produce the GOS ingredient found in probiotic products.

According to company disclosures, semiconductor-grade catalase is supplied to Samsung Electronics, SK Hynix, and TSMC, and the company is expanding market share by competing against global players Novonesis and DuPont on thermal stability and mass-production cost efficiency.

Higher value-added new products have been added, including the UDCA-manufacturing enzyme 'UDCAse' and Protease NT, used to produce collagen tripeptide.

Recently disclosed asset and revenue composition data indicate that biohealthcare materials account for roughly half of revenue, with industrial specialty enzymes as the next-largest contributor.

Subsidiary GF Fermentech supplies fermentation-based active vitamin K2 (menaquinone-7) and high-purity phytosphingosine, used in cosmetics and health foods, to global customers.

After the HLB Group acquired HLB Genex for roughly KRW 80bn in late 2024, it used the company as the hub for a broader governance restructuring that folded in additional drug-development subsidiaries.

As a result, HLB Neurotobe, which holds a central-nervous-system pipeline including dystonia candidate 'NT-1' and Parkinson's candidate 'NT-3', and HLB PEP (formerly Anygen), which operates Korea's only peptide manufacturing GMP facility and is developing the GLP-1-class obesity/diabetes candidate 'AGM-217' and the radiopharmaceutical candidate 'AGM-330', were brought under HLB Genex's governance structure.

This structure is designed to use the cash-generating enzyme business to support R&D for the still early-stage drug pipelines.

HLB Genex posted revenue of KRW 27.80bn and KRW 27.01bn in 2022 and 2023 respectively, with operating losses of KRW 6.22bn and KRW 9.46bn, driving operating margins down to -22.4% and -35.0%.

In 2024, revenue grew to KRW 35.43bn and the operating loss narrowed to KRW 1.88bn (margin of -5.3%), yet net loss attributable to owners actually widened to KRW 18.83bn and the debt ratio surged to 418.3%, a pattern consistent with temporary balance-sheet strain from the corporate restructuring that brought in new drug-development subsidiaries.

In 2025, revenue rose to KRW 43.37bn (up 22.4% year-on-year) with operating profit turning positive at KRW 1.21bn (margin 2.8%), while net income attributable to owners improved sharply to KRW 22.59bn and the debt ratio fell to 148.1%.

On a quarterly basis, however, owners' net income diverges considerably from operating income.

In Q2 2025, solid results of KRW 10.01bn revenue and KRW 1.43bn operating profit were accompanied by owners' net income of KRW 18.65bn, while Q3 2025 saw revenue of KRW 10.18bn with an operating loss of KRW 0.38bn and a net loss to owners of KRW 3.82bn.

In Q4 2025, revenue grew to KRW 12.48bn but the company posted an operating loss of KRW 0.66bn even as owners' net income reached KRW 9.06bn.

In 2026, Q1 showed revenue of KRW 11.67bn and operating profit of KRW 1.00bn alongside a net loss to owners of KRW 2.47bn, while Q2 showed revenue of KRW 11.33bn and operating profit of KRW 0.98bn with owners' net income of KRW 6.50bn.

Operating income has thus fluctuated within a narrow band of roughly plus or minus KRW 1bn over the trailing four quarters (Q3 2025 through Q2 2026), while owners' net income has swung far more widely from roughly negative KRW 3.8bn to positive KRW 9.1bn, indicating that non-operating items tied to subsidiary consolidation and equity-related gains or losses have materially influenced net income.

Disclosed H1 2026 results show health functional food revenue up more than 40% year-on-year and textile-grade catalase up in the 60% range in Q2 alone, supporting the view that product diversification is a genuine driver of top-line growth.

The industrial specialty enzyme market is tied to structural demand across several industries, including the shift toward eco-friendly semiconductor wastewater treatment, the expansion of the dairy and probiotics market, and the sophistication of pharmaceutical ingredient synthesis processes.

In the catalase market, global enzyme majors Novonesis and DuPont have long led the field, but HLB Genex appears to be pursuing market-share gains by leveraging thermal stability and fermentation-based mass-production cost competitiveness.

The utilization rates and process-expansion pace of downstream semiconductor manufacturers are variables directly linked to catalase demand, offering upside in strong industry cycles but exposing the company to demand contraction risk during downturns.

Revenue stability for products such as lactase and UDCAse depends on the extent to which food and pharmaceutical customers internalize these enzymes into their processes, and the company has recently attempted to broaden its supply footprint through an initial shipment of catalase to the US market.

Separately, the HLB Group made three attempts to win US FDA approval for the ribociclib... rather, the riboceranib plus camrelizumab combination therapy as a first-line liver cancer treatment, but received another Complete Response Letter in July 2026 citing manufacturing-site issues, and the company has stated it will pursue a fourth submission.

While this has limited direct business relevance to HLB Genex, it is a variable that can affect group-wide investor sentiment and financing conditions given the shared corporate affiliation.

The drug-development subsidiaries HLB Neurotobe and HLB PEP remain at early or preclinical stages in central-nervous-system disease and peptide-based obesity/oncology fields respectively, so global competitive intensity and clinical success rates in these areas are likely to influence medium- to long-term business value.

In its H1 2026 earnings release, the company stated it would focus on strengthening market competitiveness and management efficiency in H2 based on its diversified business portfolio.

The Korea Investors Service Research Institute forecast in a February 11, 2026 company report that HLB Genex would achieve consolidated 2026 revenue of KRW 49.5bn (up 16.8% year-on-year) and operating profit of KRW 2.6bn (up 58.7%), assessing that deeper customer-process integration of its specialty enzymes was supporting both revenue visibility and margin improvement.

Product-level growth drivers cited include the initial shipment of semiconductor-grade catalase to the North American market, expanded new applications for textile-grade catalase, and increased UDCAse supply to key partners.

At subsidiary GF Fermentech, materials such as vitamin K2 and phytosphingosine appear to be on a recovery trend.

Drug-development subsidiary HLB PEP is conducting preclinical toxicity studies in Japan for its diabetes/obesity candidate 'AGM-217', while HLB Neurotobe has stated it is pursuing joint development and licensing deals with global pharmaceutical companies for its central-nervous-system pipeline.

However, these drug pipelines remain at early or preclinical stages, and the timing of any visible revenue contribution remains uncertain.

Ultimately, near-term direction is likely to hinge on product diversification and margin trends in the existing enzyme and biomaterial businesses, while medium- to long-term direction depends on clinical and licensing progress at the drug-development subsidiaries.